Rhythm Pharmaceuticals is a late-stage biopharmaceutical company that is leading the transformation of care for people living with rare genetic disorders of obesity. Rare genetic disorders of obesity can be caused by genetic deficiencies within the melanocortin-4 receptor (MC4R) pathway, and they are characterized by early-onset, severe obesity, and insatiable hunger, also known as hyperphagia. These disorders may not be sufficiently managed by diet, exercise, or lifestyle changes alone. Currently, there are no approved therapies for these rare conditions. For more information, visit www.RhythmTx.com.